Low Evidence
Research Overview
MOTS-c Research for Metabolic Syndrome
An evidence-based overview of research examining MOTS-c in the context of metabolic syndrome. This page synthesizes findings from peer-reviewed literature.
Research Summary
MOTS-c activates AMPK and improves glucose metabolism in preclinical models. Human observational studies show lower circulating MOTS-c in Type 2 diabetes patients. No interventional trials have tested whether MOTS-c supplementation improves metabolic outcomes.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Metabolic Syndrome
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. MOTS-c has not received regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.